Sorafenib-associated Adverse Events More Common in Thyroid Cancer – Cancer Therapy Advisor

Cancer Therapy Advisor

Sorafenib-associated Adverse Events More Common in Thyroid Cancer Cancer Therapy Advisor Researchers found that the DECISION trial, as well as other phase 2 and 3 studies, demonstrated significantly higher rates of common adverse events, including hand-foot skin reaction, diarrhea, and hypertension, in patients with differentiated thyroid …

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader http://ift.tt/20M48lF
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1K35KDw
via IFTTT